ReviewJournal of pharmacy & bioallied sciences2025
To Estimate the Level of Homocysteine, Lipid Profile, and Lipid Ratio and Compare it with the Level of HS-CRP, Apo A, and ADMA in Coronary Artery Disease-Diagnosed Patients.
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD), commonly referred to as coronary heart disease (CHD), is caused by a narrowing of the primary blood vessels that supply oxygen to the heart. These vessels, called coronary arteries, can be categorized as internal and external. Common symptoms of CAD include shortness of breath and chest discomfort, which often worsen during physical exertion. Findings will contribute to future diagnostic and therapeutic strategies. The study has been approved by the institutional ethical committee IEC, on 08/07/20222, with reference number of DMIMS (DU)/IEC/2022-23/1135. The present study will shed a light on biomarkers assessment for CAD, comparing conventional markers with emerging markers for addressing its importance in the assessment of CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.